# CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type

> **NCT05218408** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Celularity Incorporated**

## Conditions studied

- Astrocytoma, Grade IV
- Glioblastoma
- Giant Cell Glioblastoma
- Glioblastoma Multiforme

## Interventions

- **BIOLOGICAL:** CYNK-001 systemic and Intra cavity administration

## Key facts

- **NCT ID:** NCT05218408
- **Lead sponsor:** Celularity Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-03-08
- **Primary completion:** 2024-02
- **Final completion:** 2024-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No enrolled subjects
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05218408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05218408, "CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05218408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*